Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2023 · 10-Q
Revenue$6.71M$6.71M+20.2% vs Q2 2022 Net Income-$83.81M-$83.81MN/M vs Q2 2022 EPS Diluted-$1.51-$1.51N/M vs Q2 2022 Operating Income-$93,700,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$66,745,000N/M Margins · derivedOperating margin-1396.0%+353.2 pt vs Q2 2022
Net margin-1248.6%+396.1 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 3, 2023 · 34 d after period end